Dyadic International, Inc. — FY 2019 Form 10-K
Business context and reporting period. This annual filing covers the year ended December 31, 2019; it does not provide a separate fourth-quarter results table. Dyadic is developing its C1 fungal gene-expression platform for biopharmaceutical applications. It has no pharmaceutical products approved for sale, and reported revenue to date is from research collaborations and government grants. Its common stock began trading on Nasdaq as DYAI in April 2019.
Financial performance and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Research and development revenue | $1.68 million | $1.30 million |
| Cost of research and development revenue | $1.46 million | $1.03 million |
| Gross profit on research revenue | $0.22 million (about 13.2% margin) | $0.27 million (about 20.7% margin) |
| Research and development expense, excluding cost of revenue and related-party R&D | $3.09 million | $2.10 million |
| Related-party R&D expense | $0.87 million | $1.22 million |
| General and administrative expense | $5.52 million | $4.52 million |
| Operating loss | $9.28 million | $7.59 million |
| Interest income | $0.98 million | $0.89 million |
| Net loss | $8.31 million ($0.31 per share) | $5.69 million ($0.21 per share) |
| Net cash used in operating activities | $5.78 million | $4.41 million |
Revenue rose about 30%, reflecting ten research collaborations versus six in 2018. However, the gross margin on research revenue declined, and the net loss widened about 46%. Higher G&A included $0.72 million more noncash share-based compensation, as well as higher business-development, insurance, legal and Nasdaq-related costs. The 2018 comparison included a $1.00 million tax benefit from the corporate AMT credit refund; 2019 recorded approximately $10,000 of tax expense.
At year-end, cash and cash equivalents were $4.82 million and investment securities were $30.91 million, for combined cash and investments of approximately $35.73 million. Current assets were $35.64 million and current liabilities $1.59 million. Stockholders’ equity was $35.86 million. The balance sheet reports no borrowings or interest-bearing debt. Management said existing cash and investments should fund operations and liquidity needs for at least the next 12 months. The accumulated deficit was $41.35 million.
Investing activities provided $7.71 million, mainly from net maturities of investment securities; financing activities provided $0.55 million, primarily from option exercises. The company reported no off-balance-sheet arrangements.
Material developments, outlook and risks
- Platform progress: Dyadic reported promising protein-expression and animal-study results, including C1 expression of an SBV antigen at approximately 1.78 g/L and reported immune responses in mice and cattle. These are company-reported development results, not evidence of regulatory approval or commercial sales.
- Glycoengineering: The company reported approximately 95% site occupancy for G0 and 76% for G2 human-like glycan structures, while noting lower expression levels in engineered strains and further work needed to achieve target glycoforms at high productivity.
- Collaborations and sublicenses: Serum Institute may evaluate up to 12 proteins and may obtain exclusive commercial sublicenses subject to funding, milestones and royalties. Sanofi was evaluating results from a proof-of-concept project. Novovet had not raised funding, so technology transfer had not occurred; Alphazyme’s transfer and qualification remained incomplete, and no related upfront sublicense revenue had been recognized.
- Research spending commitments: The VTT agreement runs through June 2022 and included EUR 2.52 million of payments over three years, an additional EUR 690,000 for glycoengineering, and a possible EUR 450,000 success bonus. The company disclosed $4.36 million of purchase obligations as of year-end, primarily for CRO services. In the first quarter of 2020, it agreed to an additional EUR 700,000 for VTT glycoengineering.
- Outlook and principal risks: The filing gives no quantitative revenue, earnings or product-launch guidance. Management expects continued operating losses and says profitability depends on scientific progress, funded research, licensing and collaborations. Key risks include clinical and regulatory hurdles, uncertain industry adoption, competition, reliance on a small number of collaborators and CROs, intellectual-property rights, and the need for additional revenue or capital over time.
- COVID-19 and contingencies: As of the financial-statement issuance date, management said operations had not been significantly affected, but the pandemic could disrupt travel, business development and third-party research. It had already contributed to delay in Alphazyme’s internal qualification. The company reported no material pending litigation. The IRS examination of the 2016 federal return was ongoing, with no issue reported to the company at that time.
- Other investor considerations: The company received approximately $0.5 million of AMT refunds in 2019 and expected further refunds through 2021. It had 3.86 million options outstanding at year-end. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Review the audited financial statements and investment-security maturity and credit details; distinguish cash from held-to-maturity investments when assessing liquidity.
- Track operating cash burn against collaboration revenue, CRO commitments and management’s stated 12-month liquidity assessment.
- Confirm whether Serum, Sanofi, Alphazyme and Novovet advance their programs, complete technology transfers, secure funding or generate license, milestone or royalty revenue.
- Assess independent evidence for C1 product quality, safety, glycosylation, reproducibility, scale-up and regulatory suitability; reported expression yields alone do not establish commercial viability.
- Monitor customer and CRO concentration, COVID-related research delays, the IRS examination, and the impact of outstanding and future equity awards on dilution.